ROS1 and non-small cell lung carcinoma: In fact, a small open-label phase II study aimed to assess the efficacy and associated toxicity of administering ceritinib in 32 patients with advanced NSCLC harboring the ROS1 rearrangement, 28 of which were evaluable for response [186].